December 2015 Vol 8, No 9
To the Editor: The study by Roy and colleagues (June 2015) presented a model framework to estimate the costs of treatment for relapsed and/or refractory multiple myeloma. We believe the assumptions applied in the study, particularly those regarding duration of therapy, lead to erroneous conclusions.
Chronic myelogenous leukemia (CML) is a hematologic cancer that occurs primarily in adults. Although CML can occur at any age, the median age at diagnosis is 64 years, and the incidence increases with age.
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
In the past 5 years, there has been a large increase in the number of employers focused on effective ways to manage the rising cost of specialty drugs. At the same time, employers have been working hard to comply with the Affordable Care Act (ACA) and are cognizant of the expected excise tax.
Joseph Tkacz, MS, Michael P. Ingham, MSc, Brenna L. Brady, PhD, Roxanne Meyer, PharmD, Charles Ruetsch, PhD
For many years, diseasemodifying antirheumatic drugs (DMARDs) have been the mainstay of RA treatment, reducing inflammation and preventing further joint deterioration and disease progression. In the past 15 years, biologic DMARDs have become available and have proved effective for reducing inflammation and managing the disease.
You Cannot Manage What You Cannot Measure
Results 1 - 6 of 6